SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Form 8-K, dated December 11, 2017, is filed by Amedica Corporation (not Sintx Technologies, Inc., as noted in the metadata request). The filing addresses a material restatement of financial statements for the fiscal year ended December 31, 2016, and the first three quarters of 2017. The Audit Committee concluded on December 8, 2017, that previously issued financial statements and the related audit report should no longer be relied upon.
Key Financial Metrics and Restatement Impact
The restatement is driven by the failure to record a derivative liability associated with warrants issued in July 2016 and January 2017, which were previously recorded as equity. This adjustment results in non-cash other expenses or income and an offsetting change to derivative liabilities. The filing provides preliminary adjusted figures (in thousands, except per share data) for key periods:
- Year Ended Dec 31, 2016: Net loss attributable to common stockholders adjusted from $(22,876) to $(21,040). Net loss per share adjusted from $(14.82) to $(13.63). Total liabilities increased by $3,137 to $15,025.
- Nine Months Ended Sept 30, 2017: Net loss attributable to common stockholders adjusted from $(7,070) to $(4,153). Net loss per share adjusted from $(2.42) to $(1.42). Total liabilities increased by $1,031 to $10,159.
- Three Months Ended Sept 30, 2017: Net loss attributable to common stockholders adjusted from $(2,815) to $(2,070). Net loss per share adjusted from $(0.93) to $(0.68).
The filing does not provide specific revenue, cash flow, or liquidity metrics for the current period, focusing solely on the restatement of losses, equity, and liabilities.
Material Changes Versus Prior Periods
The primary material change is the reclassification of warrant-related items from equity to a derivative liability. This adjustment significantly alters the reported net loss and stockholders' equity across all restated periods. For the year ended December 31, 2016, the adjustment reduced the reported net loss by $1,836. For the nine months ended September 30, 2017, the adjustment reduced the reported net loss by $2,917. Total liabilities increased in all periods due to the recognition of the derivative liability.
Outlook, Risks, and Unusual Items
Unusual Items: The filing identifies a significant accounting error regarding the classification of warrants. Additionally, the company effected a 1-for-12 reverse stock split on November 10, 2017, and all share and per-share data in the filing have been retroactively adjusted to reflect this split.
Risks and Contingencies: The company states that the listed adjustment amounts are preliminary and subject to change. There is no assurance that final adjustments will not differ materially from the estimates or that additional errors will not be identified. The company intends to file amendments to its 10-K and 10-Q reports to present the restated financial data.
Investor Verification Checklist
- Verify the final restated financial statements in the upcoming amended 10-K and 10-Q filings.
- Confirm the final valuation of the derivative liability associated with the 1,054,167 warrants issued in July 2016 and 364,708 warrants issued in January 2017.
- Review the impact of the 1-for-12 reverse stock split on current share ownership and liquidity.
- Assess the company's current liquidity position, as the filing does not provide updated cash flow or working capital data.
- Monitor for any additional accounting errors identified during the final review process.